Last reviewed · How we verify

Recombinant Herpes Zoster Vaccine — Competitive Intelligence Brief

Recombinant Herpes Zoster Vaccine (Recombinant Herpes Zoster Vaccine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: vaccine. Area: Immunology.

phase 3 vaccine Immunology Biologic Live · refreshed every 30 min

Target snapshot

Recombinant Herpes Zoster Vaccine (Recombinant Herpes Zoster Vaccine) — Beijing Luzhu Biotechnology Co., Ltd.. The recombinant Herpes Zoster Vaccine works by stimulating the body's immune system to produce a specific response against the Herpes Zoster virus.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Recombinant Herpes Zoster Vaccine TARGET Recombinant Herpes Zoster Vaccine Beijing Luzhu Biotechnology Co., Ltd. phase 3 vaccine
Comirnaty BNT162b2 (tozinameran) Pfizer Inc. marketed vaccine SARS-CoV-2 virus 2021-08-23
Prevnar 20 pneumococcal 20-valent conjugate vaccine (PCV20) Pfizer Inc. marketed Pneumococcal conjugate vaccine Streptococcus pneumoniae capsular polysaccharides (20 serotypes) 2021-06-08
PCRA (Intermittent injection) PCRA (Intermittent injection) Örebro University, Sweden marketed Cancer vaccine / Autologous cell therapy
BCG vaccine (SSI) BCG vaccine (SSI) Radboud University Medical Center marketed vaccine
Tetanus Toxoid Reduced Diphtheria Toxoid Acellular Pertussis Tetanus Toxoid Reduced Diphtheria Toxoid Acellular Pertussis Sanofi Pasteur, a Sanofi Company marketed Vaccine The vaccine targets the immune system to produce antibodies against tetanus, diphtheria, and pertussis toxins.
Fractional IPV( fIPV) Fractional IPV( fIPV) International Centre for Diarrhoeal Disease Research, Bangladesh marketed Vaccine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

Sponsor landscape (vaccine class)

  1. Pfizer · 20 drugs in this class
  2. Sanofi Pasteur, a Sanofi Company · 20 drugs in this class
  3. GlaxoSmithKline · 12 drugs in this class
  4. Merck Sharp & Dohme LLC · 12 drugs in this class
  5. Centers for Disease Control and Prevention · 9 drugs in this class
  6. Zhejiang Provincial Center for Disease Control and Prevention · 7 drugs in this class
  7. Jiangsu Province Centers for Disease Control and Prevention · 6 drugs in this class
  8. Beijing Center for Disease Control and Prevention · 6 drugs in this class
  9. International Centre for Diarrhoeal Disease Research, Bangladesh · 5 drugs in this class
  10. Sinovac Biotech Co., Ltd · 4 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Recombinant Herpes Zoster Vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/recombinant-herpes-zoster-vaccine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: